Second chance: new combo may rescue failed stem cell transplants
NCT ID NCT02161783
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of chemotherapy drugs (fludarabine and cyclophosphamide) plus low-dose radiation to prepare the body for a second stem cell transplant in people whose first transplant failed. The goal is to get the new donor cells to grow and start making blood cells by day 42. The trial enrolls 50 patients with primary or secondary graft failure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Fludarabine, Cyclophosphamide, Total Body Irradiation, and Hematopoietic stem cell infusion
What this could lead to
If successful, this could provide a reliable rescue treatment for patients whose stem cell transplant fails, helping their new immune system take hold.
What could go wrong
This is a small, early-phase study (50 people) and the regimen carries risks like infection, graft-versus-host disease, and organ damage. Success is not guaranteed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY GRAFT FAILURE are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Minnesota Medical Center, Fairview
RECRUITINGMinneapolis, Minnesota, 55455, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact